Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Source: EQS
Ad hoc announcement pursuant to Art. 53 LR
Wolfgang is currently CEO of the Swiss contract development and manufacturing organization (CDMO) Siegfried Holding AG, a role he has held since 2019. Prior to this, Wolfgang first served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Before joining Siegfried in 2010, Wolfgang held a series of increasingly senior positions at the German specialty chemicals company Evonik Industries. Wolfgang will succeed Christoph Mäder, Lead Independent Director and Vice-Chairman, Lonza, added: “Wolfgang is a high-caliber leader with outstanding CDMO experience. He will be a great asset to our business. As Wolfgang takes the role of CEO, Note to editors: About Lonza Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of Lonza Contact Details Media Inquiries: Investor Inquiries: End of Inside Information |
Language: | English |
Company: | |
Münchensteinerstrasse 38 | |
4052 |
|
Phone: | +4161 316 81 11 |
Internet: | www.lonza.com |
ISIN: | CH0013841017 |
Valor: | 1384101 |
Listed: | |
EQS News ID: | 1870895 |
End of Announcement |
|
1870895 02-Apr-